Parkinson’s disease patients now have two additional Centers of Excellence at their service: the NewYork-Presbyterian/Columbia University Medical Center in New York and the Rush University Medical Center in Chicago. The global network is run by the Parkinson’s Foundation, which supports initiatives of different types to help improve the…
News
A treatment widely used to help prevent rejection in organ transplants, called tacrolimus, appears to work to treat Parkinson’s disease (PD) and ideally should be tested in early-stage patients, researchers report. Tacrolimus, marketed under brand names including Prograf, works to suppress the immune system. It is used at high dose with…
Yoga has been shown to increase flexibility and posture, ease stiffness, and improve balance through the strengthening of core muscles in patients with Parkinson’s disease. Kaitlyn P. Roland, PhD, a yoga teacher at the Parkingo Wellness Society in Victoria, Canada, and a specialist in studies of the rehabilitative needs…
Apomorphine infusion, delivered by a portable device, helps to treat Parkinson’s disease and allows reduced use of other medications that may cause symptom fluctuations and treatment side effects. But in the long run, few patients are able to stay on the treatment for more than a few years, an Australian study shows. The study,…
Researchers have identified an interactive triangle of proteins whose activity may be regulated to prevent loss of the brain’s dopaminergic neurons, whose diminishment leads to Parkinson’s disease. One of these proteins, called PARIS, contributes to the death of the neurons. Targeting it could lead to therapies for Parkinson’s, the researchers…
A hand-grip test is one of the best measures of muscle decline in Parkinson’s disease, research indicates. Two University of British Columbia researchers, Jenn Jakobi and Gareth Jones, researched methods used to monitor the progression of Parkinson’s. Their study, “Handgrip Strength Related to Long-Term Electromyography,” was published in the…
An optimal Parkinson’s disease treatment would need to target both accelerator and brake functions in the brain to be effective without producing side effects like the jerky movements associated with L-dopa treatment. Using an advanced method to manipulate the activity in the two brain pathways that act as the accelerator…
Administering a naturally occurring growth factor to a mouse model of Parkinson’s disease reduced inflammation and prevented neurons from dying, suggesting that such factors have the potential to stop or slow the progression of disease. The study, “Activin A Inhibits MPTP and LPS-Induced Increases in Inflammatory Cell Populations…
The first patient has been dosed in a two-part Phase 1 clinical trial evaluating KM-819, Kainos Medicine’s potential disease-modifying treatment for Parkinson’s disease (PD), the company announced in a press release. The dose-escalation clinical trial (NCT03022799) will evaluate the drug’s safety, tolerability, and biochemical properties following single…
Researchers have identified more than 300 genes that influence alpha-synuclein’s toxicity, and among them are many known to predispose individuals to Parkinson’s disease (PD), researchers said. The finding provides new insight into what mechanisms lead to the disease. The hallmark of Parkinson’s disease is the formation of alpha-synuclein protein aggregates, which…
Recent Posts
- It’s time to ban paraquat, an herbicide linked to increased Parkinson’s risk
- Caregiving is also about bringing back some of what Parkinson’s takes away
- Gut protein misfolding may spot Parkinson’s years before symptoms
- I wish I could take my husband’s pain away
- Toxic protein clumps damage brain blood vessels in Parkinson’s: Study